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The hereditary spastic paraplegias (HSPs) are heteroge-
neous neurodegenerative disorders with over 50 known
causative genes. We identified a recurrent mutation in
KCNA2 (c.881G>A, p.R294H), encoding the voltage-
gated K1-channel, KV1.2, in two unrelated families with
HSP, intellectual disability (ID), and ataxia. Follow-up
analysis of> 2,000 patients with various neurological
phenotypes identified a de novo p.R294H mutation in a
proband with ataxia and ID. Two-electrode voltage-clamp
recordings of Xenopus laevis oocytes expressing mutant
KV1.2 channels showed loss of function with a dominant-
negative effect. Our findings highlight the phenotypic
spectrum of a recurrent KCNA2 mutation, implicating ion
channel dysfunction as a novel HSP disease mechanism.
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The hereditary spastic paraplegias (HSPs) are a hetero-geneous group of neurodegenerative disorders charac-
terized by spasticity and weakness in the lower extremities.
Complicated forms may also include other neurological
manifestations, such as intellectual disability (ID), epilepsy,
ataxia, polyneuropathy, optic nerve involvement, or amyo-
trophy.1 To date, over 50 genes have been identified for
HSPs, involved in axonal transport, lipid metabolism,
autophagy, myelination, DNA repair, membrane traffick-
ing and vesicle formation, cellular signaling, and protein
folding.2,3 Despite these discoveries, the genetic basis of
approximately 40% of familial HSPs remains unknown.4
Although ion channel dysfunction plays an important
role in the pathogenesis of other disorders of the central
nervous system, including the epilepsies5 and ataxias,6,7 to
date ion channels have not been implicated in HSPs.
De novo gain-of-function and dominant-negative
mutations in KCNA2, encoding the Shaker-type voltage-gated
potassium channel, KV1.2, have recently been implicated in
early-onset epileptic encephalopathies.8–10 KCNA2 belongs to
the KV1 subfamily of voltage-gated potassium channels that
plays a crucial role in the repolarizing phase of action poten-
tials and neuronal excitability. Kv channel subunits contain six
transmembrane helices (S1–S6), comprising a voltage-sensing
(S1–S4) and pore (S5–S6) domain. They form homomeric or
heteromeric channels. KV1.2 channels are expressed in both
excitatory and inhibitory neurons and are concentrated in
axon initial segments and axon terminals.11,12
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Here, we report on a novel recurrent missense muta-
tion within the Kv1.2 voltage sensor associated with variable
phenotypes, including hereditary spastic paraplegia, ataxia,
and ID.
Materials and Methods
Patients
Family 1 was referred for diagnostic whole-exome sequencing
(WES) at Ambry Genetics (Aliso Viejo, CA). Family 2 underwent
WES as part of an ongoing research study investigating the genetic
basis of HSP. One hundred three unrelated HSP patients previous-
ly screened for major genetic causes of HSP, including SPAST,
ATL1, and KIAA0196, were used as a follow-up cohort. Existing
trio-based WES data of approximately 1,500 patients with various
neurological disorders and 500 with epilepsy were assessed as a sec-
ond follow-up cohort. Informed consent was obtained for all par-
ticipants and parents, where applicable. This study was approved
by the local institutional review boards of the participating centers.
Sequencing
WES of the family quad for family 1 (proband, mother, father,
and son) was performed as previously described.13 Before WES,
the proband from family 1 had undergone sequencing of PLP1,
SPAST, and ATL1, deletion/duplication analysis of PLP1, and
SPAST deletion analysis, which were all negative. For family 2,
WES data were annotated and imported into GENESIS/
GEM.app, a web-based tool for next-generation sequencing
NGS data analysis.14 In brief, the GENESIS/GEM.app includes
the curated WES and whole-genome data from approximately
6,000 individuals/families with various neurological diseases.
Candidate alterations were confirmed in available family members
using automated fluorescence dideoxy sequencing. Sequencing
of KCNA2 in the follow-up cohort of 103 HSP probands was
performed by automated fluorescence dideoxy sequencing.
Functional Analysis
To engineer the mutations into human KCNA2, complementary
(cDNA) site-directed mutagenesis was performed using Quick-
Change (Agilent Technologies, Santa Clara, CA). Xenopus laevis
oocytes were injected with mutant and/or wild-type (WT) comple-
mentary RNA (cRNA). After 2 days of incubation, potassium cur-
rents were recorded using an automated two-electrode voltage
clamp system (Roboocyte2; Multi Channel Systems, Reutlingen,
Germany) as described previously.8 Experiments were approved by
the local Animal Care and Use Committee (Regierungspr€asidium
T€ubingen, Germany).
Results
Mutation Analysis
WES in families 1 and 2 identified the c.881G>A
(p.R294H) mutation, predicting substitution of a highly
conserved arginine for histidine, located in the voltage
sensor-forming S4 transmembrane segment of KCNA2
(Fig 1A,B). The mutation segregates with the phenotype
of spastic paraplegia in all affected individuals in an
autosomal-dominant fashion (Fig 1C). The c.881G>A
(p.R294H) alteration has not been reported in over
60,000 individuals in the Exome Aggregation Consor-
tium and is predicted to be deleterious by in silico pre-
diction models (PolyPhen and SIFT). Family 2 was the
only family in the GENESIS/GEM.app data set with the
p.R294H KCNA2 mutation. Sequencing of KCNA2 in
the follow-up cohort of 103 patients with HSP did not
identify any additional mutations. Screening of WES
data from the second follow-up cohort of approximately
2,000 individuals with neurological disorders identified a
de novo c.881G>A (p.R294H) mutation in 1 affected
sister with ataxia and ID from a family with 2 siblings
with early-onset absence epilepsy (Fig 1C).
FIGURE 1: (A) Structure of the voltage-gated potassium chan-
nel, Kv1.2, with transmembrane segments S1 to S4 forming the
voltage sensor domain (light gray) and segments S5 and S6
forming the pore region (dark gray) with its pore-forming loop
and location of p.R294H mutation, within transmembrane seg-
ment S4, which constitutes the voltage sensor. (B) Evolutionary
conservation of R294 amino acid residue and neighboring R297
and L298, which have been implicated in epileptic encephalopa-
thies. (C) Pedigrees of all three families with identified p.R294H
mutations along with cosegregation data. WT5wild type. [Col-
or figure can be viewed in the online issue, which is available at
www.annalsofneurology.org.]
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Clinical Characteristics
Clinical features are detailed in Supplementary Table 1.
FAMILY 1. Family 1 consists of 3 individuals with HSP
and mild cognitive deficits (Patients 1, 2, and 3). The
proband (Patient 1) was a 32-year-old woman at the time
of study inclusion with a clinical diagnosis of HSP, begin-
ning around age 5 years. Her lower-limb spasticity has
been progressive and she became wheelchair dependent by
age 19. She had learning disabilities with slow processing
speed and reported increasing impairment of fine motor
skills. The proband’s son (Patient 2) was 6 years old at the
time of inclusion into our study and had onset of lower-
limb spasticity at age 2 years, global developmental delays,
and a diagnosis of autism spectrum disorder. The proband’s
mother (Patient 3) had mild intellectual disability and a
clinical diagnosis of HSP beginning around age 5 years.
Her lower-limb spasticity has been progressive and she
became wheelchair dependent by age 45 years. A routine
electroencephalogram (EEG) revealed focal epileptiform
discharges, but no clinical seizures.
FAMILY 2. Family 2 consists of a mother/son pair with
HSP and limb and gait ataxia (Patient 4, Patient 5).
Patient 4 was 49 years old at inclusion in our study. He
was diagnosed with a progressive gait disorder with fre-
quent falls, abnormal gait pattern, and lower-limb spas-
ticity at age 5 years. He had low normal intellect with
increasing memory deficits, and a routine EEG showed
focal epileptiform discharges without clinical seizures.
Patient 5 had normal cognition; she had onset of spastic-
ity at age 30 years and is able to walk independently. She
also has a sensory-motor axonal demyelinating peripheral
neuropathy. Both mother and son exhibit action tremor.
FAMILY 3. In family 3, both sisters had early-onset
absence epilepsy and ID. The mutation-positive proband
from family 3 (Patient 6) presented with limb and gait
ataxia as well as hand tremor and fine motor difficulties at
3 years, which were not present in the mutation-negative
sister. In addition, the mutation-positive sister had several
prolonged febrile seizures beginning at 15 months; the
mutation-negative sister only had a single febrile seizure.
Spasticity was not noted in Patient 6 at age 20.
Functional Analysis
Current amplitudes derived from p.R294H mutant chan-
nels showed a dramatic decrease compared to those from
WT (Fig 2A). Coexpression of WT and p.R294H mutant
channels in different ratios with a constant amount of
injected WT cRNA revealed significantly decreased current
amplitudes in comparison to the same amount of WT
cRNA injected alone, indicating a dominant-negative
effect of mutant on WT channels (Fig 2A,B). In addition,
we observed a depolarizing shift of the activation curve
derived from mutant channels, consistent with a further
loss of channel function (Fig 2C).
Discussion
We identified a recurrent missense mutation in KCNA2
in two unrelated families with complicated HSP and in
FIGURE 2: Functional effects of the p.R294H KCNA2mutation.
(A) Recordings of currents elicited by increasing voltage steps
from a holding potential of –80mV from Xenopus laevis oocytes
expressing either WT KV1.2 channels (left), R294H mutant chan-
nels (center), or both (right). (B) Amplitudes of recorded currents
normalized to the mean current amplitude of the WT. Ampli-
tudes decreased with increasing amounts of injected mutant
cRNA, whereas the amount of WT cRNA remained constant,
suggesting a dominant-negative effect on WT channels. Groups
were statistically different (one-way ANOVA: p<0.001; post-
hoc Dunn’s method: p<0.05). Shown aremeans6SEM. (C) Acti-
vation curves of WT, R294H mutant, and a 1:1 expression of
both clones, showing a significantly different shift to more-
depolarized potentials for mutant channels, consistent with a
loss-of-channel function (one-way ANOVA: p<0.001; post-hoc
Dunn’s method: p<0.05). Shown are means6SEM. Lines repre-
sent Boltzmann functions fit to data points. ANOVA5 analysis
of variance; cRNA5 complementary RNA; SEM5 standard error
of the mean; WT5wild type. [Color figure can be viewed in the
online issue, which is available at www.annalsofneurology.org.]
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1 individual with ataxia, tremor, and ID. Functional
analysis of the p.R294H mutation revealed a dominant-
negative loss of KV1.2 channel function, similar to other
mutations, which we described recently outside the volt-
age sensor (p.I263T, p.P405L) causing epileptic encepha-
lopathy. This is in contrast to the strong KV1.2 channel
gain of function of the neighboring p.R297Q and
p.L298F mutations.8 The highly conserved R294 residue
is the first of seven positively charged, evenly spaced gat-
ing charges in the voltage-sensing S4 segment, the move-
ment of which causes the central KV1.2 pore to open
and allow K1 ions to pass through based on their elec-
trochemical gradient.15–17 Mutations at these conserved
arginine residues in the voltage-sensing domain have
been demonstrated in other model systems to lead to ion
leakage across the membrane and lead to a conductance,
also known as omega current, which is distinct from the
main pore ionic current.18,19 Substitution of the first S4
arginine of the Shaker potassium channel for histidine,
equivalent to the p.R294H mutation in KCNA2, causes
an abnormal proton (omega) current at hyperpolarized
potentials, which is absent in WT channels.18,20
These findings suggest that the p.R294H mutation in
KCNA2 results in loss of normal KV1.2 function and leads
to a proton conduction at hyperpolarized potentials.20
This may explain the neurodegenerative phenotype associ-
ated with the p.R294H mutation and account for the phe-
notypic difference in p.R294H mutation carriers compared
to patients with (1) other mutations outside the voltage
sensor (p.I263T, p.P405L) or (2) other gain-of-function
voltage sensor mutations (p.R297Q, p.L298F), who have
epileptic encephalopathies.8
The phenotypic spectrum of the p.R294H mutation
carriers is intriguing. Two of the identified families had
complicated HSP. However, the phenotype of Patient 6
from family 3 is perplexing. Patient 6 is 1 of 2 sisters with
early-onset absence epilepsy, but, unlike her affected sister,
had a de novo p.R294H mutation in KCNA2 and had atax-
ia and tremor as the distinguishing features. This suggests
that another cause of the early-absence epilepsy exists in
this family. Patient 6 did not have lower-extremity spastici-
ty at 20 years. Given the variable age of onset of spasticity
in families 1 and 2, Patient 6 may not yet have developed
spasticity. Alternatively, the phenotypic spectrum of the
KCNA2 p.R294H mutation may involve other movement
disorders, such as ataxia, in addition to spastic paraplegia.
There is some phenotypic overlap between the patients
presented here and patients with other mutations in
KCNA2,8,9 in particular, cognitive impairment (families 1,
2, and 3), ataxia (families 2 and 3), impairment of fine
motor skills (families 1 and 3), tremor (families 2 and 3),
and prolonged febrile seizures (family 3). Although
epilepsy was not a feature of the currently described fami-
lies, focal epileptiform discharges on EEG were observed in
patients from all three families, suggesting an underlying
susceptibility to seizures. Spasticity does not appear to be a
feature in previously reported patients with KCNA2
encephalopathy. However, a recently reported patient with
epileptic encephalopathy and a de novo c.1120A>G
(p.T374A) KCNA2 mutation was found to have axial
hypotonia with appendicular spasticity at 28 months,
compatible with spastic quadriplegia.10 Although this
early-onset spastic quadriplegia is clinically distinct from
the slowly progressive HSP in the families reported on
here, this observation suggests that Kv1.2 dysfunction in
patients with epileptic encephalopathies may also lead to
degeneration of the corticospinal tracts. Description of
further patients with KCNA2 mutations will delineate the
full spectrum and assess whether phenotypes overlap or are
mutation specific.
Ion channel dysfunction is linked to a number of
disorders from cardiac arrhythmias to epilepsies. However,
so far, ion channel dysfunction has not been described in
the hereditary spastic paraplegias. Accordingly, identifying
two unrelated HSP families with an identical KCNA2
mutation expands the channelopathy spectrum and
demonstrates a novel disease mechanism.
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